Uppsala Reports editor
@UMCGlobalSafety
Medicine safety monitoring applies to all aspects of drug development, but how much is it impacted by patient diversity and study type in clinical trials?
Medicine safety monitoring is important in every stage of drug development, from pre-marketing clinical trials to post-marketing analyses. Yet, certain factors in their design can greatly impact its effectiveness, such as the diversity of the study population, or the complexity of its methodology.
All this and more is discussed in the latest Drug Safety Matters podcast episode, where Marianne Lunzer from AGES and Sanja Prpić from HALMED, review the pros and cons of various study types and the importance of testing medicines on diverse populations, as well as how pre and post-marketing studies are linked to give a more comprehensive picture of patient safety.
Subscribe by visiting the Drug Safety Matters website or listen to the podcast here:
Uppsala Reports editor
@UMCGlobalSafety
An Australian research team is using artificial intelligence to improve the safe dosing of unfractionated heparin, a high-risk drug linked to serious side effects.
30 March 2026
Analysis of paired reports from the Norwegian ADR Registry suggests merging consumer and healthcare professional accounts of the same adverse event may improve causality assessment
19 August 2026
Complementary medicines are widely used and often perceived as safe, yet high doses, product stacking, and unclear labelling can quietly increase the risk of harm.
07 April 2026